EFFICACY OF ONCE A MONTH SINGLE DOSE INTRAVENOUS (DEFEROXAMINE) VERSUS DAILY ORAL (DEFERASIROX) IRON CHELATOR IN THALASSEMIA MAJOR: AN OPEN LABEL RANDOMIZED PARALLEL GROUP ACTIVE CONTROL INTERVENTIONAL TRIAL

Dr Ratna Bhojak, Dr Jayendra Gohil, Dr Mehul Gosai, Dr Bibin Varghese

Abstract


Objective: Compare efficacy of Once a Month Single Dose Intravenous (Deferoxamine) with Daily Oral (Deferasirox) Iron Chelator in Thalassemia Major.
Methodology: In this open label trials Patients were randomized by chit method after informed consent and allocated to two groups. Group A was
administered Inj Deferoxamine by intravenous route once during monthly blood transfusions and Group B received Tab Deferasirox administered
daily. The monitoring was done by serum Ferritin level every two months.
Results: The primary outcome was decrease in ferritin level over 6 months from the baseline. Decrease in serum ferritin (%) over six months for
Group A was 46±18 and Group B was 25±17 with significant difference between the two groups (p=0.001). The cost of treatment per kilo weight
was not significantly different.
Conclusion: We observed that Intravenous Deferoxamine once a month is a better and cheaper iron chelator as compared to the daily subcutaneous regimen;


Full Text:

PDF

References


Baun M, Jones M, Elliott V. Thalassemia Syndromes. Behrman R, MD (eds) Nelson Textbook of Pediatrics, 20/ed. Philadelphia: ELSEVIER; 2016. p. 2349.

Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997;89:739.

Alymara V, Bourantas D, Chaidos A, Bouranta P, Gouva M, Vassou A, et al. Effectiveness and safety of combined iron-chelation therapy with Deferoxamine and Deferiprone. Hematol J 2004;5(6):475-9.

Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, et al. Randomized controlled trial of Deferiprone or Deferoxamine in beta-Thalassemia major patients with asymptomatic myocardial siderosis. Blood. 2006; May 1, 107(9):3738-44.

Alessia Pepe, Antonella Meloni, Marcello Capra, Paolo Cianciulli, Luciano Prossomariti, Cristina Malaventura,et al. Deferasirox, Deferiprone And Desferrioxamine Treatment In Thalassemia Major Patients: Cardiac Iron And Function Comparison Determined By Quantitative Magnetic Resonance Imaging. Haematologica. January 2011; 96: 41-47.

D Cappellini, M Bejaoui, L Agaoglu, D Canatan, M Capra, A Cohen, et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. Blood. 2011; 118:884-93.

Piga A, Galanello R, Forni GL, Cappellini M, Origa R, Zappu A, et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica. 2006; Jan 1; 91(7):873-80.

Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia. Blood. 2006; May 1; 107(9):3455-62.

Walter PB, Macklin EA, Porter J, Evans P, Kwiatkowski JL, Neufeld EJ, et al. Inflammation and oxidant-stress in β-thalassemia patients treated with iron chelators Deferasirox (ICL670) or Deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. Haematologica. 2008; Jun 1; 93(6):817-25.


Refbacks

  • There are currently no refbacks.